On 17 July 2026 the board of Samsung Biologics Co., Ltd. (KRX:207940) resolved to acquire PolyPeptide Group AG, a Swiss-listed contract manufacturer of peptides, through a tender offer at CHF 44.31 per share. Four independent directors attended and none were absent. The filing went to Korea's DART three days later and was amended on 28 August.
The size is what makes it worth reading closely. The offer targets 33,016,411 shares, every share outstanding net of treasury, for CHF 1,462,957,171 — about ₩2,706.2bn at the CHF/KRW rate of 1,849.79 used in the filing, or roughly $1.9bn at a working rate near ₩1,400 to the dollar. Samsung Biologics puts that at 24.47% of its own total assets and 36.32% of its equity.
And PolyPeptide has lost money for three straight years.
The condensed financials Samsung Biologics attached are unusually blunt for a deal announcement. Converted at the July rates in the filing: FY2025 revenue ₩669.2bn, net loss ₩36.1bn. FY2024 revenue ₩578.4bn, net loss ₩33.4bn. FY2023 revenue ₩554.6bn, net loss ₩87.8bn. Total equity has fallen each year, from ₩650.9bn to ₩609.9bn to ₩581.5bn, while total liabilities climbed from ₩525.6bn to ₩828.7bn. BDO signed unqualified opinions on all three.
So the picture is a business growing revenue in the mid-to-high single digits, consuming equity, and adding debt. Samsung Biologics is offering roughly four times FY2025 sales and about 4.7 times book equity for it.
The mechanics are conditional. The offer only completes if irrevocably tendered shares reach about 66.7% of fully diluted capital. Draupnir Holding B.V., a Dutch entity holding 18,375,000 shares or 55.65%, has committed to tender everything it owns, which gets most of the way there on its own. Settlement is scheduled for 30 November 2026, subject to merger control and foreign investment approvals. Samsung Biologics may run the bid through a Swiss subsidiary it has yet to establish.
Samsung Biologics does not make peptides. It makes proteins, in living cells, in stainless steel bioreactors — 845,000 litres of installed capacity across Songdo and a site in Rockville, Maryland. Peptides are made differently. They are short chains of amino acids assembled chemically, usually by solid-phase synthesis, and the plant looks more like a fine chemicals facility than a bioreactor hall. Different equipment, different regulatory files, different engineers.
Why buy in? Because peptides are where the demand went. GLP-1 drugs — semaglutide, tirzepatide, the obesity and diabetes medicines that reordered pharmaceutical revenue over the past four years — are peptides. The manufacturing bottleneck for that class has been one of the tightest in the industry, and every large drug company has been signing multi-year supply agreements to lock in capacity.
A monoclonal antibody CDMO watching that from the outside has two options. Build a peptide plant, which takes years and produces no revenue until qualified. Or buy one that already has approved facilities, validated processes and customers. Samsung Biologics has historically chosen to build. It built Plants 1 through 5 faster than anyone thought possible and made a virtue of it. This is a departure.
The departure is the tell. Buying rather than building says the company thinks the window closes before a greenfield plant could open.
The external valuation deserves a paragraph. Deloitte Anjin worked from 14 to 17 July — four days, including a weekend — and concluded that the per-share value falls somewhere between CHF 31.43 and CHF 63.22. The opinion then says the CHF 44.31 offer price is not, from a materiality standpoint, inappropriate, given precedent control premiums on listed companies.
The top of that range is double the bottom. An appraisal that wide does not really constrain a price; it certifies that a number sits inside a wide corridor. Korean fairness opinions on cross-border deals are often like this, and the four-day turnaround suggests the work confirmed a price already negotiated rather than informing it. Investors should read it as a compliance document, not as evidence the price is right.
That said, CHF 44.31 sits below the midpoint of the range, which is at least not aggressive on the appraiser's own terms.
Samsung Biologics is buying from a position of real operating strength. FY2025 revenue was ₩4,557.0bn with operating income of ₩2,069.2bn, a 45.4% operating margin, and net income of ₩1,784.4bn. The second quarter of 2026 brought ₩1,320.9bn of revenue and ₩586.4bn of operating income, a 44.4% margin. Operating cash flow was ₩2,247.8bn in FY2025 and ₩2,160.2bn in just the first half of 2026.
It is also, in one specific respect, not liquid. Cash and equivalents were ₩288.6bn at the end of the second quarter, against ₩148.9bn at the end of FY2025. This is a company that runs its cash thin because it spends it on plants: purchases of property, plant and equipment were ₩1,391.7bn in FY2025 and ₩1,303.6bn in FY2024. Property, plant and equipment now stands at ₩6,468.0bn, more than half of total assets.
That explains the funding switch. The original 20 July filing said the tender would be paid from own funds and borrowings. The 28 August amendment changed that to funds raised through a rights offering, and the same day the board approved a ₩3.0tn issue of 2,270,000 new shares, of which ₩2,706.2bn is earmarked for exactly this acquisition.
A margin like Samsung Biologics' does not mean cash is sitting idle. It means the cash keeps going into concrete.
The bull case does not require PolyPeptide to be a good business today. It requires the capacity to be worth more inside Samsung than outside it.
There is a version where that is obviously true. PolyPeptide's losses come with a heavy fixed-cost base and utilization that has never filled it. Samsung Biologics' entire operating history is a case study in filling plants — Plants 1 through 4 at Songdo are reported at full utilization, and the company's 45% margins come from running assets hot. If it can point its existing pharmaceutical client list at a peptide facility that was running half-empty, the acquired losses turn quickly. Contract manufacturing is a utilization business more than a pricing business.
There is also the customer-relationship argument. The same large pharmaceutical companies that buy antibody capacity from Samsung buy peptide capacity from someone. Selling both to one procurement department is worth something real.
Against that: Samsung has never integrated a foreign manufacturing business of this size, the Rockville site it bought is itself still being stabilized by the company's own account, and Swiss operations come with a cost base and labour framework nothing in Songdo prepares you for. Three years of losses under the current owner is not a fact you fix with enthusiasm.
The tender result first, expected around the 30 November settlement date. If acceptances land only just above the 66.7% minimum, Samsung ends up with a listed Swiss subsidiary and minority holders to manage, which is a worse outcome than the clean 100% the filing contemplates.
After that, the number to watch is PolyPeptide's utilization, which Samsung Biologics will have to disclose in some form once it consolidates. Not revenue — utilization. A peptide plant at 50% and a peptide plant at 85% are the same asset with entirely different economics, and the whole thesis rests on which one Samsung can produce.
The FY2027 results are the first that will contain a full year of it. If group operating margin holds anywhere near 40% with PolyPeptide inside, the acquisition worked. If it drops toward the mid-30s and stays there, Samsung Biologics paid ₩2.7tn to dilute the best margin structure in contract manufacturing.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.